What ORIC Pharmaceuticals does

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with a research footprint in San Diego. The company is publicly traded on NASDAQ under the ticker ORIC following its April 2020 IPO. ORIC is organized around a proprietary resistance platform that targets three distinct mechanisms by which cancers evade therapy — innate resistance (unaddressed oncogenic drivers), acquired resistance (treatment-induced drivers), and bypass resistance (compensatory signaling) — with the goal of extending the clinical benefit of existing and emerging cancer treatments.

The pipeline consists of four differentiated small-molecule programs. The lead asset, rinzimetostat (ORIC-944), is an allosteric inhibitor of PRC2 via the EED subunit designed to address resistance in metastatic castration-resistant prostate cancer; Phase 1b data showed 55% PSA50 response rate and 59% ctDNA clearance, with the 400mg dose plus darolutamide selected for the 600-patient Himalayas-1 registrational Phase 3 trial initiating in H1 2026. Enozertinib (ORIC-114) is a brain-penetrant irreversible EGFR inhibitor targeting exon 20 insertion and PACC mutations in NSCLC, with reported 67–80% ORR in EGFR-mutant disease and intracranial activity; it is being evaluated both as monotherapy and in combination with J&J's amivantamab. Earlier-stage assets include ORIC-533 (CD73 inhibitor for multiple myeloma, in a Pfizer clinical collaboration) and ORIC-613 (PLK4 inhibitor in preclinical development for TRIM37-high tumors).

The business model is pre-commercial: ORIC generates no product revenue today, and access to its investigational compounds is restricted to patients enrolled in clinical trials across ten-plus countries. Future revenue, contingent on regulatory approval, is expected to come from direct pharmaceutical sales supplemented by out-licensing or co-promotion arrangements (consistent with the Pfizer and Janssen clinical collaborations already in place). The company has raised more than $900 million in private and public capital since 2018, holds $413 million in cash extending runway into H2 2028, and is led by a management team and board with a track record of developing and exiting oncology assets at Ignyta (Roche), Aragon (J&J), Seragon (Roche), Medivation (Pfizer), and Pharmacyclics.

Name

ORIC Pharmaceuticals

Legal name

Oric Pharmaceuticals, Inc.

Website

https://oricpharma.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapies that target cancer resistance mechanisms, with a lead Phase 3 program (rinzimetostat) in prostate cancer and a brain-penetrant EGFR inhibitor (enozertinib) in NSCLC, both addressing major unmet needs in oncology.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Oncology drug development
• Cancer resistance therapies
• Precision oncology medicines
• PRC2 inhibitors
• EGFR inhibitors

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: ORIC Pharmaceuticals is a pre-revenue clinical-stage biopharmaceutical company. The company is focused on developing innovative cancer therapies with the goal of achieving regulatory approval and commercializing products. Revenue will be generated through sales of approved pharmaceutical products once clinical trials are successfully completed and regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule oncology therapies designed to overcome cancer resistance. Its pipeline targets three resistance categories — innate, acquired, and bypass — and includes an allosteric PRC2/EED inhibitor (rinzimetostat) for metastatic castration-resistant prostate cancer, a brain-penetrant EGFR inhibitor (enozertinib) for NSCLC with exon 20 and PACC mutations, a CD73 inhibitor (ORIC-533) for multiple myeloma, and a preclinical PLK4 inhibitor (ORIC-613). All candidates are investigational and currently accessed only through clinical trials.

Product overview

ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing therapies that address cancer resistance mechanisms. The company's resistance platform targets three areas: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced/enriched oncogenic drivers from treatment), and bypass resistance (compensatory signaling pathways). The clinical-stage portfolio includes: Rinzimetostat (ORIC-944), a PRC2 allosteric inhibitor via EED subunit for prostate cancer; Enozertinib (ORIC-114), a brain-penetrant EGFR inhibitor for NSCLC with EGFR exon 20 and PACC mutations; ORIC-533, a CD73 inhibitor for multiple myeloma; and ORIC-613, a PLK4 inhibitor in preclinical development for TRIM37-high cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Rinzimetostat (ORIC-944) A potent and selective allosteric inhibitor of PRC2 via the EED subunit designed to have superior drug properties over EZH2 inhibitors, including longer clinical half-life, robust target engagement, and a favorable safety profile. Efficacious in ARPI-sensitive and -resistant prostate cancer models and being developed for patients with metastatic castration-resistant prostate cancer who have progressed after abiraterone, in combination with androgen receptor pathway inhibitors such as darolutamide and apalutamide. Demonstrated 55% PSA50 response rate, 59% ctDNA clearance, and 84% 5-month radiographic progression-free survival at the selected Phase 3 dose.
• Enozertinib (ORIC-114) A brain-penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR with high potency against exon 20 insertion mutations and atypical PACC mutations. Demonstrates greater brain exposure compared with other compounds and strong anti-tumor activity in intracranial lung cancer models. Being developed for NSCLC patients with EGFR exon 20 insertions, PACC mutations, and other atypical EGFR mutations, including those with CNS metastases, as monotherapy and in combination with amivantamab and chemotherapy. Demonstrated 67–80% ORR in EGFR-mutant NSCLC and 35% ORR in HER2 exon 20 mutated NSCLC with mostly Grade 1–2 adverse events.
• ORIC-533 A small molecule CD73 inhibitor with potential best-in-class properties being developed for multiple myeloma. Designed to reverse immunosuppression and act as an immunomodulatory therapy. Being advanced through clinical development in collaboration with Pfizer.
• ORIC-613 A potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor demonstrating synthetic lethality in TRIM37-high cancer models, including neuroblastoma and breast cancer. Currently in preclinical development.

Quantifiable outcome

• Rinzimetostat 55% PSA50 response rate in metastatic castration-resistant prostate cancer patients
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Johnson & Johnson (Janssen)coreStrategic or Co-development Partner · 24 February 2026Clinical trial collaboration with Johnson & Johnson's Janssen unit to evaluate enozertinib (ORIC-114) in combination with amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab) in patients with first-line NSCLC with EGFR exon 20 insertion mutations.
• PfizercoreStrategic or Co-development Partner · 22 December 2022Clinical development collaboration with Pfizer for a Phase 2 study of ORIC-533 in multiple myeloma. Pfizer made a $25 million equity investment in ORIC. The collaboration leveraged Pfizer's capabilities to advance ORIC-533 into combination therapy with Pfizer's elranatamab, extending ORIC's cash runway into H1 2025.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Highly comparable to ORIC given overlapping interest in PRC2/epigenetic biology, similar development stage, and comparable small molecule oncology strategy.
• Revolution Medicines: Clinical-stage precision oncology company developing novel targeted therapies including RAS(ON) inhibitors. Comparable in size, public-stage, clinical focus, and emphasis on differentiated mechanisms of action addressing cancer resistance and difficult targets.
• Black Diamond Therapeutics: Clinical-stage precision oncology company developing medicines against undrugged targets, including allosteric and mutant-selective approaches. Directly comparable in clinical-stage model, mechanism-driven discovery, and small-molecule strategy.
• Kura Oncology: Clinical-stage precision oncology company developing menin inhibitors (ziftomenib) and tipifarnib for HRAS-mutant tumors. Comparable size, stage, and clinical-stage precision oncology model targeting defined genetic patient populations.
• Erasca: Clinical-stage precision oncology company developing MAPK pathway inhibitors. Highly comparable as a public clinical-stage biotech with multiple programs in oncology addressing defined resistance mechanisms in a similar development profile.
• Nuvalent: Clinical-stage precision oncology company developing kinase inhibitors including zidesamtinib for ROS1 and neladalkib for ALK in NSCLC. Directly comparable to ORIC's enozertinib in CNS-active EGFR targeting and clinical-stage model.

Broad incumbents

• Astellas Pharma: Global pharma owner of Xtandi (enzalutamide), the leading ARPI for mCRPC. Direct competitive incumbent in the indication where ORIC's rinzimetostat Phase 3 will compete, with established commercial infrastructure and payer access.
• Bayer: Global pharma that owns Nubeqa (darolutamide), the ARPI being combined with ORIC's rinzimetostat in the Phase 3 Himalayas-1 trial. As the combination partner, Bayer is both a strategic ally and an entrenched competitor in mCRPC.
• Ipsen: Global oncology-focused pharma that acquired Epizyme, gaining tazemetostat (EZH2 inhibitor, an FDA-approved PRC2 inhibitor for epithelioid sarcoma and follicular lymphoma). Direct mechanism competitor to ORIC's rinzimetostat in PRC2 oncology.
• Daiichi Sankyo: Global pharma developing valemetostat (EZH1/2 dual inhibitor) for lymphoma. A direct epigenetic mechanism competitor in the PRC2 inhibitor space and a major oncology innovator with ADC and other targeted programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oric-pharmaceuticals-inc
• Xx.com/oricpharma
• Facebookfacebook.com/768122476654325

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds8 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ORIC Pharmaceuticals